ASLAN Pharmaceuticals Limited reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 13.51 million compared to USD 14.48 million a year ago. Basic loss per share from continuing operations was USD 0.75 compared to USD 1 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3169 USD | -0.97% | -22.71% | -39.30% |
Jun. 20 | Asian Equities Traded in US as American Depositary Receipts Gain in Thursday Trading | MT |
Jun. 18 | Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.30% | 7.17M | |
+15.19% | 121B | |
+19.91% | 114B | |
+8.24% | 23.61B | |
-19.80% | 20.43B | |
-16.19% | 16.55B | |
-13.45% | 16.45B | |
-44.35% | 15.59B | |
+66.67% | 15.19B | |
+2.13% | 13.54B |
- Stock Market
- Equities
- ASLN Stock
- News ASLAN Pharmaceuticals Limited
- ASLAN Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 2023